Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    MoonLake Immunotherapeuti...

    NASDAQ: MLTX · Real-Time Price · USD
    42.92
    -1.29 (-2.92%)
    At close: Jun 16, 2025, 3:59 PM
    44.08
    2.70%
    After-hours: Jun 16, 2025, 06:42 PM EDT

    MoonLake Immunotherapeutics Statistics

    Share Statistics

    MoonLake Immunotherapeutics has 63.47M shares outstanding. The number of shares has increased by 0.65% in one year.

    Shares Outstanding

    n/a
    		 63.47M

    Shares Change (YoY)

    n/a
    		 0.65%

    Shares Change (QoQ)

    n/a
    		 0.35%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 52.94M

    Failed to Deliver (FTD) Shares

    n/a
    		 1

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 6.31M, so 9.94% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 6.31M

    Short % of Shares Out

    n/a
    		 9.94%

    Short % of Float

    n/a
    		 22.32%

    Short Ratio (days to cover)

    n/a
    		 29.01

    Valuation Ratios

    The PE ratio is -0.03 and the forward PE ratio is -12.13. MoonLake Immunotherapeutics's PEG ratio is 0.

    PE Ratio

    n/a
    		 -0.03

    Forward PE

    n/a
    		 -12.13

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 2.2

    PB Ratio

    n/a
    		 0.01

    P/FCF Ratio

    n/a
    		 -29.07

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for MoonLake Immunotherapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 0.02, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 0.02

    Quick Ratio

    n/a
    		 0.02

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 -0.02

    Debt / FCF

    n/a
    		 -0.02

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,206,800.02

    Employee Count

    n/a
    		 100

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 282.2K

    Effective Tax Rate

    n/a
    		 -0.23%

    Stock Price Statistics

    The stock price has increased by 6.88% in the last 52 weeks. The beta is 1.23, so MoonLake Immunotherapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.23

    52-Week Price Change

    n/a
    		 6.88%

    50-Day Moving Average

    n/a
    		 39.97

    200-Day Moving Average

    n/a
    		 45.57

    Relative Strength Index (RSI)

    n/a
    		 54.87

    Average Volume (20 Days)

    n/a
    		 539,577

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -143.09M

    Net Income

    n/a
    		 -120.68M

    EBITDA

    n/a
    		 -119.58M

    EBIT

    n/a
    		 n/a

    Earnings Per Share (EPS)

    n/a
    		 -1919.51
    Full Income Statement

    Balance Sheet

    The company has 180.43M in cash and 2.83M in debt, giving a net cash position of 177.6M.

    Cash & Cash Equivalents

    n/a
    		 180.43M

    Total Debt

    n/a
    		 2.83M

    Net Cash

    n/a
    		 177.6M

    Retained Earnings

    n/a
    		 -235.59B

    Total Assets

    n/a
    		 511.26M

    Working Capital

    n/a
    		 482.28M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -116.59M and capital expenditures -519.52K, giving a free cash flow of -117.11M.

    Operating Cash Flow

    n/a
    		 -116.59M

    Capital Expenditures

    n/a
    		 -519.52K

    Free Cash Flow

    n/a
    		 -117.11M

    FCF Per Share

    n/a
    		 -1.86
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    MLTX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for MLTX is $73, which is 64.9% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $73

    Price Target Difference

    n/a
    		 64.9%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 8
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 14.6

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist